Notice: Takeda Pharmaceutical to Cut 400 US Jobs in Overhaul Ahead of First Female CEO Taking Charge

Takeda Pharmaceutical Company, Japan's largest drugmaker, announced in March 2026 that it will eliminate approximately 400 positions in its United States operations as part of a comprehensive restructuring ahead of a leadership transition scheduled for June 2026, Nikkei Asia reported. The layoffs are set to begin on 1 July 2026.

What the company announced

The restructuring forms part of a broader overhaul estimated at approximately $1.3 billion, as Takeda refocuses its portfolio on priority therapeutic areas including blood products, immunology and rare diseases. Alongside the job cuts, the company is investing $230 million in new production facilities at its Los Angeles plant, signalling a shift toward higher-value manufacturing rather than pure cost reduction.

• Approximately 400 US positions to be eliminated
• Layoffs effective from 1 July 2026
• Part of a broader restructuring estimated at ~$1.3 billion
• $230 million investment in new Los Angeles production facilities
• Refocus on blood products and priority therapeutic areas
• Leadership transition: Julie Kim becomes CEO in June 2026 — the company's first female chief executive

Leadership transition

The restructuring precedes the appointment of Julie Kim as president and CEO in June 2026, making her the first woman to lead the 245-year-old company. Kim previously served as a senior executive within the organisation and is expected to continue the strategic refocus initiated under outgoing CEO Christophe Weber, who has led the company since 2015 and oversaw the transformative $62 billion acquisition of Shire in 2019.

Industry context

Takeda's move comes amid a broader wave of pharmaceutical industry restructuring globally, as companies face patent cliffs on blockbuster drugs, rising research costs and pressure from investors to improve returns on capital. The Japanese pharmaceutical sector has seen increasing consolidation and portfolio rationalisation, with companies divesting non-core assets to fund innovation in priority areas. Takeda's investment in blood-derived therapies positions it in a market with high barriers to entry and relatively stable demand.

Company details

Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK), headquartered in Osaka, Japan. Official website: takeda.com.